HealthdirectFree Australian health advice you can count on.

•Patients should be monitored for any new malignancies(cancer) prior to starting the treatment and up to six months after completing the treatment with cobimetinib. • Patients should be monitored for any signs and symptoms of bleeding. • Patients should be monitored for any signs and symptoms of heart problems as the risk of cardiomyopathy is increased in patients receiving cobimetinib along with vemurafenib compared with vemurafenib as a single agent. • Patients should be monitored for severe skin rashes.‍‍‍‍‍‍​​​‍​​​​​​ Reduce or discontinue cobimetinib in case rashes appear. • Visual evaluation should be done at regular intervals and for any visual disturbances. Permanently discontinue cobimetinib in case of confirmed retinal vein occlusion. • Patients are advised to inform any signs and symptoms of rhabdomyolysis (muscle protein breakdown) like muscle pain, fever, dark urine or confusion. • Advise patients to avoid sun exposure. • To help protect against sunburn - wear clothes that protect skin, including head, face, hands, arms, and legs. Sunscreen should be used while going out. • Advise females of the reproductive age group to use effective contraception when on this medication.